Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Invested Capital (2017 - 2025)

Historic Invested Capital for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $645.4 million.

  • Protagonist Therapeutics' Invested Capital rose 2134.21% to $645.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $645.4 million, marking a year-over-year increase of 2134.21%. This contributed to the annual value of $675.3 million for FY2024, which is 10057.65% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Invested Capital of $645.4 million as of Q3 2025, which was up 2134.21% from $668.0 million recorded in Q2 2025.
  • Over the past 5 years, Protagonist Therapeutics' Invested Capital peaked at $689.1 million during Q1 2025, and registered a low of $215.6 million during Q4 2022.
  • Its 5-year average for Invested Capital is $407.2 million, with a median of $329.7 million in 2021.
  • As far as peak fluctuations go, Protagonist Therapeutics' Invested Capital soared by 25688.49% in 2021, and later plummeted by 2845.17% in 2023.
  • Quarter analysis of 5 years shows Protagonist Therapeutics' Invested Capital stood at $300.0 million in 2021, then fell by 28.14% to $215.6 million in 2022, then soared by 56.15% to $336.7 million in 2023, then surged by 100.58% to $675.3 million in 2024, then fell by 4.42% to $645.4 million in 2025.
  • Its last three reported values are $645.4 million in Q3 2025, $668.0 million for Q2 2025, and $689.1 million during Q1 2025.